These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28028730)

  • 1. Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.
    Han K; Chanu P; Jonsson F; Winter H; Bruno R; Jin J; Stroh M
    AAPS J; 2017 Mar; 19(2):527-533. PubMed ID: 28028730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
    Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
    BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
    Spigel DR; Ervin TJ; Ramlau RA; Daniel DB; Goldschmidt JH; Blumenschein GR; Krzakowski MJ; Robinet G; Godbert B; Barlesi F; Govindan R; Patel T; Orlov SV; Wertheim MS; Yu W; Zha J; Yauch RL; Patel PH; Phan SC; Peterson AC
    J Clin Oncol; 2013 Nov; 31(32):4105-14. PubMed ID: 24101053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
    J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
    Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
    Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.
    Kishi K; Sakai H; Seto T; Kozuki T; Nishio M; Imamura F; Nokihara H; Satouchi M; Nakagawa S; Tahata T; Nakagawa K
    Cancer Treat Res Commun; 2019; 18():100113. PubMed ID: 30472556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.
    Hirsch FR; Govindan R; Zvirbule Z; Braiteh F; Rittmeyer A; Belda-Iniesta C; Isla D; Cosgriff T; Boyer M; Ueda M; Phan S; Gandara DR
    Clin Lung Cancer; 2017 Jan; 18(1):43-49. PubMed ID: 27461773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
    Smit EF; Wu YL; Gervais R; Zhou C; Felip E; Feng J; Guclu SZ; Hoiczyk M; Dorokhova E; Freudensprung U; Grange S; Perez-Moreno PD; Mitchell L; Reck M
    Lung Cancer; 2016 Sep; 99():94-101. PubMed ID: 27565921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new drug in thoracic oncology: MetMab (onartuzumab)].
    Giroux Leprieur É
    Rev Pneumol Clin; 2013 Jun; 69(3):152-8. PubMed ID: 23477747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
    Penuel E; Li C; Parab V; Burton L; Cowan KJ; Merchant M; Yauch RL; Patel P; Peterson A; Hampton GM; Lackner MR; Hegde PS
    Mol Cancer Ther; 2013 Jun; 12(6):1122-30. PubMed ID: 23536720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
    Xin Y; Jin D; Eppler S; Damico-Beyer LA; Joshi A; Davis JD; Kaur S; Nijem I; Bothos J; Peterson A; Patel P; Bai S
    J Clin Pharmacol; 2013 Nov; 53(11):1103-11. PubMed ID: 23922054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.
    Spigel DR; Edelman MJ; Mok T; O'Byrne K; Paz-Ares L; Yu W; Rittweger K; Thurm H;
    Clin Lung Cancer; 2012 Nov; 13(6):500-4. PubMed ID: 23063071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
    Koeppen H; Yu W; Zha J; Pandita A; Penuel E; Rangell L; Raja R; Mohan S; Patel R; Desai R; Fu L; Do A; Parab V; Xia X; Januario T; Louie SG; Filvaroff E; Shames DS; Wistuba I; Lipkind M; Huang J; Lazarov M; Ramakrishnan V; Amler L; Phan SC; Patel P; Peterson A; Yauch RL
    Clin Cancer Res; 2014 Sep; 20(17):4488-98. PubMed ID: 24687921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
    Cicènas S; Geater SL; Petrov P; Hotko Y; Hooper G; Xia F; Mudie N; Wu YL
    Lung Cancer; 2016 Dec; 102():30-37. PubMed ID: 27987585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.
    Nishio M; Horiike A; Nokihara H; Horinouchi H; Nakamichi S; Wakui H; Ohyanagi F; Kudo K; Yanagitani N; Takahashi S; Kuboki Y; Yamamoto N; Yamada Y; Abe M; Tahata T; Tamura T
    Invest New Drugs; 2015 Jun; 33(3):632-40. PubMed ID: 25777467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
    Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
    EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
    Reckamp KL; Koczywas M; Cristea MC; Dowell JE; Wang HJ; Gardner BK; Milne GL; Figlin RA; Fishbein MC; Elashoff RM; Dubinett SM
    Cancer; 2015 Sep; 121(18):3298-306. PubMed ID: 26033830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
    Smit EF; Garon EB; Reck M; Cappuzzo F; Bidoli P; Cohen RB; Gao L; O'Brien LM; Lee P; Zimmermann A; Ferry DR; Melemed AS; Pérol M
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):77-86. PubMed ID: 29721850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onartuzumab ineffective in non-small-cell lung cancer.
    Brower V
    Lancet Oncol; 2017 Feb; 18(2):e66. PubMed ID: 28017663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.